Scientists and public health experts are calling the approval of new antibiotics a major milestone in the fight against drug-resistant gonorrhea—a sexually transmitted infection affecting over 82 million people worldwide each year, according to The Guardian.

Gonorrhea was long considered easily treatable, but growing bacterial resistance to existing antibiotics has made it a global health threat. The World Health Organization has classified the gonorrhea pathogen as a high-priority, serious-risk pathogen.

In mid-December 2025, the U.S. Food and Drug Administration (FDA) approved the use of new antibiotics, including zoliflodacin (marketed as Nuzolvence) and gepotidacin. Zoliflodacin was developed through a collaboration between the non-profit Global Antibiotic Research & Development Partnership (GARDP) and Innoviva, while gepotidacin belongs to a new class of antibiotics effective against multidrug-resistant strains. Clinical trials showed that zoliflodacin cures over 90% of genital gonorrhea cases without serious side effects, making its efficacy comparable to existing combination therapies.

Experts are particularly interested in zoliflodacin because it is a single-dose oral medication, greatly simplifying treatment compared to current standard therapies, which require injections followed by additional doses. The drug will also be available in low- and middle-income countries, where the burden of gonorrhea is particularly high.

According to specialists, the approval is seen as a turning point in efforts to slow the spread of antibiotic-resistant strains and prevent serious complications such as infertility and chronic inflammatory diseases. However, the global community emphasizes that this is only part of a broader fight against antibiotic resistance, which requires strengthened surveillance, responsible drug use, and continued innovation.